Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay | Zendy

Katariiward | Zendy; Linnea Ek Blom | Zendy; Lina Davies Forsman | Zendy; Judith Bruchfeld | Zendy; Erik Eliasson | Zendy; Thomas Schön | Zendy; Erja Chryssanthou | Zendy; Jakob Paues | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay

Author(s) -

Katariiward,

Linnea Ek Blom,

Lina Davies Forsman,

Judith Bruchfeld,

Erik Eliasson,

Thomas Schön,

Erja Chryssanthou,

Jakob Paues

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00218-18

Subject(s) - tuberculosis , drug , medicine , liter , pharmacology , rifampicin , therapeutic drug monitoring , plasma levels , pathology

The plasma tuberculosis drug activity (TDA) assay may be an alternative tool for therapeutic drug monitoring in resource-limited settings. In tuberculosis (TB) patients ( n = 30), TDA and plasma levels of first-line drugs were analyzed 2 h postdose, 2 weeks after treatment initiation. Patients with plasma levels of rifampin lower than 8 mg/liter had a significantly lower median TDA (1.40 versus 1.68, P = 0.0013). TDA may be used to identify TB patients with suboptimal rifampin levels during TB treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research